Liposome-based diclofenac for the treatment of inflammation in an acute synovitis model in horses.

This research article explores the use of liposome-based diclofenac, a type of NSAID, for managing inflammation related to joint disease in horses. The study used several biomarkers to measure the effect of the treatment, but found that there was no overall difference between the diclofenac treatment and control groups.

Introduction to the Study

• This research focuses on the problem of lameness in horses, which is often due to joint diseases. The condition affects horses’ athletic performance severely and thus requires effective treatment.
• Commonly, nonsteroidal anti-inflammatory drugs (NSAIDs) are used in treatment routines. Phenylbutazone is the go-to NSAID in most cases, but it carries the risk of severe side effects.
• Therefore, the researchers turned their attention to diclofenac, an NSAID contained in a liposome-based formulation. Previous studies indicated that this treatment formulation could be a safer and more convenient option for managing lameness, particularly that associated with osteoarthritis.

Purpose of the Study

• The main objective of the study was to examine the impact of topically applied liposome-based diclofenac on an acute inflammation model. This involved subjective lameness assessments and the objective evaluation of lameness, using carpal circumference and surface temperature, synovial fluid cell count, total protein content, and certain inflammation markers (IL-1, IL-6, prostaglandin E(2)).

Findings of the Study

• The outcomes of the study were not as expected, resulting in no discernible difference between the groups treated with diclofenac and those that were not (control group).
• This implies that in this particular model of acute inflammation, liposome-based diclofenac did not exhibit any significant anti-inflammatory or other effects that would imply benefit for treating joint disease-induced lameness in horses.